Evidence map›Paper›PMID 40945433›Full record

ArticleHematology, transfusion and cell therapy

Overall survival in multiple myeloma in Brazil: A cohort of 16 years.

Deborah Marta do Santos Oliveira, Isabela Cristina Menezes de Freitas, Wallace Mateus Prata, Isabella Zuppo Laper, Pâmela Santos Azevedo, Adriano de Paula Sabino, Marisa Yurico Itonaga, Carmino Antonio de Souza, Mariângela Leal Cherchiglia, Juliana Alvares Teodoro and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematology, transfusion and cell therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Deborah Marta do Santos OliveiraFaculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. Electronic address: dmsoliveira17@gmail.com.
Isabela Cristina Menezes de FreitasFaculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Collaborating Centre for Technology Assessment in Health and Excellence (CCATES), Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Wallace Mateus PrataFaculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Research and Development Directorate of the Ezequiel Dias Foundation, Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Isabella Zuppo LaperFaculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Collaborating Centre for Technology Assessment in Health and Excellence (CCATES), Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Pâmela Santos AzevedoFaculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Collaborating Centre for Technology Assessment in Health and Excellence (CCATES), Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Adriano de Paula SabinoFaculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Marisa Yurico ItonagaHealth Consultant Specialized in Oncology, São Paulo, Brazil.
Carmino Antonio de SouzaHematology and Hemotherapy Center, University of Campinas, São Paulo, Brazil.
Mariângela Leal CherchigliaDepartment of Preventive and Social Medicine at the Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Juliana Alvares TeodoroFaculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Collaborating Centre for Technology Assessment in Health and Excellence (CCATES), Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Francisco de Assis AcurcioFaculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Collaborating Centre for Technology Assessment in Health and Excellence (CCATES), Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Augusto Afonso Guerra JuniorFaculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Collaborating Centre for Technology Assessment in Health and Excellence (CCATES), Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. Electronic address: augustoguerrajr@ufmg.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma constitutes approximately 1 % of all malignancies, with a higher incidence observed in over 65-year-old individuals. New technologies have shown promising results with an increased overall survival. The objective of this cohort study was to evaluate the survival analysis of patients with multiple myeloma treated by the Brazilian Unified Health Service over 16 years and compare the effectiveness of bortezomib (Bortezomib)-based treatment with other regimens used. A retrospective national cohort study was conducted utilizing real-world evidence derived from the Brazilian Unified Health System big data. This study focused on 25,370 patients with multiple myeloma who underwent chemotherapy between 2000 and 2015. Of these patients, 50.71 % were male, and the median age was 62 years. The median overall survival was 37 months. Hematopoietic stem cell transplantation (HSCT) was the best prognostic factor with overall survival of 87 months. The bortezomib (Bortezomib)-based chemotherapy provided the best results of the different chemotherapy regimens in terms of overall survival (67 months), followed by thalidomide-based schemes with an overall survival of 54 months. Despite the significant progress made in the Brazilian health system, the National Committee for Technology Incorporation (CONITEC) needs to make quicker decisions to improve access to new oncology drugs for patients, while maintaining rigorous evaluation criteria. Earlier adoption and adequate funding for oncology services could have saved more lives compared to the treatments made available by the Unified Health Service at that time.

Indexed as

Cohort studiesMedical record linkageMultiple myelomaReal world evidenceSurvival analysis

Identifiers

PMID40945433
PMCPMC12570202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.